Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01-STEM in Muscle Atrophy Related to Knee Osteoarthritis
NCT05211986Phase 2Completed
- Sponsor
- Immunis, Inc.
- Start
- Sep 2022
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMM01-STEM in muscle atrophy (4 cohorts), sponsored by Immunis, Inc. Primary endpoint: Safety of IMM01-STEM treatment. Started Sep 2022; status: completed.
02
Drugs
IMM01-STEM
03
Conditions
muscle atrophy
Beyond the preview
Go deeper on NCT05211986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05211986.